DSM : 1Q21 EBITDA 4% beat; expect 2021 consensus +2%
>1Q21 adjusted EBITDA 4% ahead of consensus - DSM reported better than expected 1Q21 trading update. Sales of € 2,194m were up 7% yoy and 2% ahead of consensus (Vara). Volumes were up 9%, while price/mix was down 1%. Adjusted EBITDA of € 441m was up 13% yoy and 4% ahead of consensus. Nutrition revenues were up 7% yoy at € 1,678m, 1% ahead of consensus. Adjusted EBITDA of € 352m was up 9% yoy and 1% ahead of consensus, as the EBITDA margin was 10bps below consensus at ...Royal DSM is engaged in the creation of products and services in Life Sciences and Materials Sciences. Co.'s products and services are used globally in range of markets and applications in healthcare, pharmaceutical automotive and chemicals sectors. End markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrics and electronics, life protection and housing. The activities of Co. are grouped into four clusters: Nutrition, Pharma, Performance Materials and Polymer Intermediates.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.